Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: The Mild to Moderate Kidney Disease Study

Kidney International

Volumn 71, Issue 12, 2007, Pages 1279-1286

  Kollerits, B ^a   Fliser, D ^b   Heid, I M ^c,d   Ritz, E ^e   Kronenberg, F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adiponectin; Kidney disease; Metabolic syndrome; Progression

Indexed keywords

ADIPONECTIN; CREATININE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEINURIA; ROC CURVE; SEX DIFFERENCE;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 34250026176     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002191     Document Type: Article

References (42)

1. Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987; 31: 1153-1159.
2. Diamond JR, Karnovsky MJ. A putative role of hypercholesterolemia in progressive glomerular injury. Annu Rev Med 1992; 43: 83-92.
3. Rabin KR, Kamari Y, Avni I et al. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 2005; 3: 465-471.
4. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
5. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
6. Menzaghi C, Ercolino T, Di PR et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002; 51: 2306-2312.
7. Costacou T, Zgibor JC, Evans RW et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2005; 48: 41-48.
8. Schulze MB, Shai I, Rimm EB et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54: 534-539.
9. Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
10. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-174.
11. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic Adults. J Am Soc Nephrol 2005; 16: 2134-2140.
12. Becker B, Kronenberg F, Kielstein JT et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the Mild and Moderate Kidney Disease Study. J Am Soc Nephrol 2005; 16: 1091-1098.
13. Fliser D, Kronenberg F, Kielstein JT et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. J Am Soc Nephrol 2005; 16: 2456-2461.
14. Boes E, Fliser D, Ritz E et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. J Am Soc Nephrol 2006; 17: 528-536.
15. Lee CT, Lee CH, Su Y et al. The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. Int J Artif Organs 2004; 27: 835-841.
16. Shen Y, Peake PW, Kelly JJ. Should we quantify insulin resistance in patients with renal disease? Nephrology (Carlton) 2005; 10: 599-605.
17. Isobe T, Saitoh S, Takagi S et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol 2005; 153: 91-98.
18. Zoccali C, Mallamaci F, Panuccio V et al. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl 2003; 63(Suppl 84): S98-S102.
19. Lawlor DA, Davey SG, Ebrahim S et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005; 90: 5677-5683.
20. Lindsay RS, Resnick HE, Zhu J et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005; 25: e15-e16.
21. Shimada K, Miyauchi K, Mokuno H et al. Predictive value of the adipocyte-derived plasma protein adiponectin for restenosis after elective coronary stenting. Jpn Heart J 2002; 43: 85-91.
22. Sattar N, Wannamethee G, Sarwar N et al. Adiponectin and coronary heart disease. A prospective study and meta-analysis. Circulation 2006; 114: 623-629.
23. Kanaya AM, Wassel FC, Vittinghoff E et al. Serum adiponectin and coronary heart disease risk in older black and white americans. J Clin Endocrinol Metab 2006; 91: 5044-5050.
24. Laughlin GA, Barrett-Connor E, May S et al. Association of adiponectin with coronary heart disease and mortality. Am J Epidemiol 2006.
25. Schalkwijk CG, Chaturvedi N, Schram MT et al. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 2006; 91: 129-135.
26. Pilz S, Mangge H, Wellnitz B et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006; 91: 4277-4286.
27. Menon V, Li L, Wang X et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2599-2606.
28. Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762.
29. Qi Y, Takahashi N, Hileman SM et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529.
30. Kalantar-Zadeh K, Abbott KC, Kronenberg F et al. Epidemiology of dialysis patients and heart failure patients. Semin Nephrol 2006; 26: 118-133.
31. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451.
32. Furuhashi M, Ura N, Moniwa N et al. Possible impairment of transcardiac utilization of adiponectin in patients with type 2 diabetes. Diabetes Care 2004; 27: 2217-2221.
33. Wang Y, Xu A, Knight C et al. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 2002; 277: 19521-19529.
34. Reynolds K, He J. Epidemiology of the metabolic syndrome. Am J Med Sci 2005; 330: 273-279.
35. Ong KK, Frystyk J, Flyvbjerg A et al. Sex-discordant associations with adiponectin levels and lipid profiles in children. Diabetes 2006; 55: 1337-1341.
36. Pajvani UB, Du X, Combs TP et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085.
37. Kahn R, Buse J, Ferrannini E et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48: 1684-1699.
38. Vionnet N, Tregouet D, Kazeem G et al. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes 2006; 55: 3166-3174.
39. Heid IM, Wagner SA, Gohlke H et al. Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1727 healthy Caucasians. Diabetes 2006; 55: 375-384.
40. Kronenberg F, Kuen E, Ritz E et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105-115.
41. Bostom AG, Kronenberg F, Ritz E. Predicitive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13: 2140-2144.
42. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.